Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: GlobeImmune Clear all

Conditions: NSCLC
Interventions: GI-4000; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Hepatitis C
Interventions: GI-5005; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Pasadena, California • Denver, Colorado • Miami, Florida + 2 more

Conditions: Colon Cancer
Interventions: chemotherapy and GI-4000, GI-4000; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreas Cancer
Interventions: GI-4000, Gemcitabine; Biological · Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more

Search by objective public record fields.

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer